# OnCo record motixafortide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/motixafortide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "motixafortide" ;
  schema:name "Motixafortide"@en ;
  schema:alternateName "BL-8040"@en, "BKT140"@en, "Aphexda" ;
  schema:description "Motixafortide is an injection given with G-CSF before stem cell collection in people with multiple myeloma, approved in the United States in 2023, so that enough stem cells for an autologous transplant can be harvested in one or two sessions."@en ;
  schema:url <https://onco.cc/drugs/motixafortide/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Motixafortide> ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217159>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=motixafortide>, <https://en.wikipedia.org/wiki/Motixafortide> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "CXCR4 antagonist peptide, subcutaneous injection" ;
  onco:approval "US 2023: With filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in multiple myeloma" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:drugs <https://onco.cc/drugs/filgrastim/>, <https://onco.cc/drugs/plerixafor/> ;
  onco:companies <https://onco.cc/companies/biolinerx/> ;
  onco:trials <https://onco.cc/trials/nct06514508/> .